RxDoctor Payments Data

Melissa Schepp

Psychiatric/Mental Health · Minot, NDNPI 1134687874

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 45 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 24.8% of the total.

$797in general payments, 2019–2025

Across 45 payments — averaging $17.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$198
  • AbbVie$160
  • Teva Pharmaceuticals USA, Inc.$103
  • Lundbeck LLC$91
  • Alkermes, Inc.$89
  • Otsuka America Pharmaceutical, Inc.$66
  • plus $90 from 4 others

What the payments were for

  • Food & beverage$797100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$797 in reported general payments places this provider in the 75th percentile of 92 psychiatric/mental health providers in North Dakota.

See all psychiatric/mental health providers in North Dakota

Medicare billing

Part B allowed, 2024
$6,148
Medicare patients
28
Services billed
81

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl17$23,850
Olanzapine OdtOlanzapine13$5,895
Quetiapine Fumarate85$2,347
Duloxetine Hcl40$1,831
Sertraline Hcl49$1,554
Buspirone Hcl44$884
Fluoxetine Hcl22$871
Trazodone Hcl60$798
Bupropion XlBupropion Hcl18$528
Escitalopram Oxalate43$453
Clonazepam36$440
Olanzapine19$431
Lamotrigine16$349
Lithium Carbonate ErLithium Carbonate13$321
Trihexyphenidyl Hcl14$220

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$160$23,85017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 92 psychiatric/mental health providers in North Dakota.

Other psychiatric/mental health in Minot

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →